Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations

European Urology
Catherine H MarshallEmmanuel S Antonarakis

Abstract

Poly ADP-ribose polymerase (PARP) inhibitors, such as olaparib, are being explored as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) in men harboring mutations in homologous recombination DNA-repair genes. Whether responses to PARP inhibitors differ according to the affected gene is currently unknown. To determine whether responses to PARP inhibitors differ between men with BRCA1/2 and those with ATM mutations. This was a multicenter retrospective review of 23 consecutive men with mCRPC and pathogenic germline and/or somatic BRCA1/2 or ATM mutations treated with olaparib at three academic sites in the USA. The proportion of patients achieving a ≥50% decline in prostate-specific antigen (PSA50 response) was compared using Fisher's exact test. Clinical and radiographic progression-free survival (PFS) and overall survival were estimated using Kaplan-Meier analyses and compared using the log-rank test. The study included two men with BRCA1 mutations, 15 with BRCA2 mutations, and six with ATM mutations. PSA50 responses to olaparib were achieved in 76% (13/17) of men with BRCA1/2 versus 0% (0/6) of men with ATM mutations (Fisher's exact test; p=0.002). Patients with BRCA1/2 mutations had median PFS of ...Continue Reading

References

Dec 10, 2002·Trends in Molecular Medicine·Andrew Tutt, Alan Ashworth
Dec 18, 2007·Molecular Cell·J Wade Harper, Stephen J Elledge
Apr 15, 2011·Nature Chemical Biology·Philip M ReaperJohn R Pollard
Nov 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bella KaufmanSusan M Domchek
Jul 19, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey KimRichard Pazdur
Oct 29, 2015·The New England Journal of Medicine·Joaquin MateoJohann S de Bono
Feb 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group 3
Apr 19, 2016·American Journal of Human Genetics·Brennan DeckerElaine A Ostrander
Mar 6, 2018·Journal of the National Cancer Institute·Britta WeigeltGeorgia Chenevix-Trench
Apr 4, 2018·Nature Genetics·Joshua ArmeniaEliezer M Van Allen

❮ Previous
Next ❯

Citations

Jul 4, 2019·Proceedings of the National Academy of Sciences of the United States of America·Bin GuiLi Jia
Dec 19, 2019·Pharmacogenomics·Eric JohnsonUmang Swami
Mar 14, 2020·Current Opinion in Oncology·Catherine H Marshall, Emmanuel S Antonarakis
Jun 11, 2020·Expert Review of Anticancer Therapy·Mark C Markowski, Emmanuel S Antonarakis
Apr 28, 2020·International Journal of Cancer. Journal International Du Cancer·Tú Nguyen-DumontMelissa C Southey
Sep 5, 2020·Expert Review of Molecular Diagnostics·Fernando López-CamposFelipe Couñago
Jul 28, 2020·International Journal of Molecular Sciences·Andreia BrandãoManuel R Teixeira
Jun 15, 2019·Prostate Cancer and Prostatic Diseases·Wenhao ZhangJulie Nonnekens
Jan 25, 2020·Current Oncology Reports·Alexandra O Sokolova, Heather H Cheng
Aug 28, 2020·The New England Journal of Medicine·Johann de BonoMaha Hussain
May 25, 2020·Nature Reviews. Clinical Oncology·Emmanuel S Antonarakis
Mar 3, 2020·Frontiers in Oncology·Rohan GarjeYousef Zakharia
Jun 10, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Veda N GiriLeonard G Gomella
Oct 30, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nadine M TungJudy E Garber
Aug 28, 2020·Journal of the National Cancer Institute·Burcu F DarstChristopher A Haiman
Feb 23, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wassim AbidaSimon Chowdhury
Jul 23, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Harsimar KaurTamara L Lotan
Jun 4, 2020·Cancer Research·Jeremy S Setton, Simon N Powell
Feb 20, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zsofia SztupinszkiZoltan Szallasi
Jan 20, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Tamara L LotanEmmanuel S Antonarakis
Jan 25, 2020·Cancer Treatment and Research Communications·Catherine Handy Marshall, Emmanuel S Antonarakis
Feb 17, 2021·Acta Pharmacologica Sinica·Yi-Xin ChenZhao-Qian Liu
Mar 27, 2021·Future Oncology·Corinne Maurice DrorKim N Chi
Apr 9, 2021·Expert Opinion on Pharmacotherapy·Benjamin L Maughan, Emmanuel S Antonarakis
Apr 19, 2021·Nuclear Medicine and Biology·Magdalena StaniszewskaWolfgang P Fendler
Jul 3, 2021·Cancers·Lauren K JillsonScott D Cramer
Jul 3, 2021·The Urologic Clinics of North America·Matthew J Schiewer, Karen E Knudsen
Jul 3, 2021·The Urologic Clinics of North America·Brian T Helfand, Jianfeng Xu
Aug 11, 2021·Surgical Pathology Clinics·Ibrahim KulacMichael C Haffner
May 15, 2021·Journal of the National Comprehensive Cancer Network : JNCCN·Baijun DongWei Xue
Aug 26, 2021·Computational and Structural Biotechnology Journal·Tarcisio FedrizziFrancesca Demichelis
May 29, 2021·Cancer Discovery·Suzanne CarreiraJohann S de Bono
Aug 21, 2021·Molecular Cancer Therapeutics·Mitchell G LawrenceLuc Furic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.